Abstral REMS Sets Stage For Risk Reduction Plans For Similar Fentanyls
Executive Summary
FDA's decision to create a class Risk Evaluation and Mitigation Strategy for all transmucosal fentanyl products indicates that the agency could take a similar strategy with the extended-release opioids.
You may also be interested in...
FDA Standardizing REMS Re-Enrollment Procedures
Common registration site for participants in REMS was endorsed by several panel members during a joint meeting of the Drug Safety and Risk Management and Dermatologic and Ophthalmic Drugs Advisory Committees.
iPLEDGE Again On FDA Advisory Agenda, This Time As An Example
"REMS-related topics" is the theme of a joint FDA advisory committee meeting Dec. 1 focused on the landmark iPLEDGE program as an example of the effect such programs have on the health care system.
Drug Patch Manufacturers Can Skip Quality By Design Approach, FDA Says
Final guidance softens a recommendation that manufacturers of transdermal and transmucosal drug delivery systems and topical patches use a Quality by Design approach.